U.S. Markets close in 2 hrs 5 mins

ChromaDex Corporation (CDXC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.42-0.54 (-6.78%)
As of 1:55PM EDT. Market open.
Sign in to post a message.
  • C
    CS
    @ $7.00 CDXC = 6X PS/R on this years revenue estimates.

    That valuation removes almost all of the speculation value from the recent spike, and returns it to ~ the equivalent speculative valuation we saw in the $4-5 range.

    I'm a scale-in buyer in the < $7.00 area, if that occurs.

    The speculation around Walmart may be too high here, but it isn't nothing, and there are many potential other, as yet unrecognized catalysts. Where, for example, is the EU roll-out? There, we DO HAVE regulatory approval, the one year trial period is up. Yes, Covid impact is still real, but that shouldn't stop a wider on-line presence with Watsons new strategy (online + offline). We need to hear an update on this from Fried.
  • M
    Marshmallow
    Here's an idea for a fad diet recipe to help NAFLD.
    Hot chocolate made with Hershey's cocoa powder, and some Tru Niagen. (Not a joke.)
    Liver heaven.

    "In findings recently published in the Journal of Nutritional Biochemistry, the researchers reported that cocoa-treated mice gained weight at a 21% lower rate and had smaller spleen weights -- indicating less inflammation -- than the high-fat-fed control mice. At the end of the study, mice fed the cocoa-powder-supplemented diet had 28% less fat in their livers than the control mice. Cocoa-treated mice also had 56% lower levels of oxidative stress and 75% lower levels of DNA damage in the liver compared to high-fat-fed control mice."
    https://www.sciencedaily.com/releases/2021/04/210414154933.htm
  • J
    Joe
    https://pubmed.ncbi.nlm.nih.gov/33871064/
    Inhibition of CD38 and supplementation of nicotinamide riboside ameliorate lipopolysaccharide-induced microglial and astrocytic neuroinflammation by increasing NAD
    Neuroinflammation is initiated by activation of the brain's innate immune system in response to an inflammatory challenge. Insufficient control of neuroinflammation leads to enhanced or prolonged pathology in various neurological conditions including
    Neuroinflammation is initiated by activation of the brain's innate immune system in response to an inflammatory challenge. Insufficient control of neuroinflammation leads to enhanced or prolonged pathology in various neurological conditions including
    pubmed.ncbi.nlm.nih.gov
  • M
    MICHAEL
    Gotta be honest. Researched Fadi and he’s impressive. If Rob let’s him do his thing fast and launch this product correctly at WMT, this could be a rocket ride much faster than us jaded long-term investors could hope for. CDXC is a buy here.
  • R
    Richard
    Gearing up for WalMart launch!!! I created a new topic only because I don't think it has resonated why the CMO hire is so important. We are probably less than 2 months away from the TRU Niagen launch at WalMart. ChromaDex has already said that they are going to have to rely on their own abilities to get the message out to WalMart shoppers. I assume Fadi has just started work at ChromaDex... his first assignment will undoubtedly be to drive WalMart sales. I think the move is excellent... during the interview process, Fadi must have convinced management that he can get this moving... let's see what he has in store.
  • A
    Anne
    Skin care, beauty, and TruNiagen:
    This skin care practitioner has done a good job describing how Niagen helps repair damage to the skin. I know for a fact that, after 8 years taking TruNiagen, my skin has not aged, although I still have to wear a hat when in the sun. I'd like to catch up from all the years spent in the high desert without wearing a hat. It does seem to be happening. https://lumeskin.com/nicotinamide-riboside/
  • M
    Marshmallow
    YF is blocking me on posting a link to the 9 EH trials listed on ClinicalTrials.
    Isn't that interesting?
    My posts have been deleted now 3 times.
  • M
    Marshmallow
    This is a 3 minute video clip I found on a US Amazon page
    for the single bottle of Tru Niagen (30 count for $47.30).
    Title is "I have more energy, and my hair changed from grey to brown!"

    https://smile.amazon.com/vdp/d48b8168f8014afe827d0f9c89cf7130?ref=dp_vse_rvc_0
    I have more energy, and my hair changed from grey to brown!
    I have more energy, and my hair changed from grey to brown!
    smile.amazon.com
  • A
    Anne
    Exciting news on the new CMO. His connection to Nestle is a big deal. Chromadex connection to Nestle is a big deal. Chromadex connection to Walmart is a big deal. Walmart connection to Nestle products is a big deal. I'm all in until it reaches at least $200 a share, which it WILL...
  • C
    CS
    This article incorrectly refers to the Oct. ScandiBio study as a Phase I, and ignores the successful Phase III study completed in Feb.

    It does show a positive secondary endpoint analysis in progression to severe illness which the ScabndiBio study did not address.

    Romark eyes an EUA with new phase III COVID-19 outpatient data
    April 14, 2021

    “There is a big need for a drug in outpatients. If you could treat them and keep them out of hospitals, that would be important and play a big role in getting us through this pandemic,” Romark Laboratories LC’s CEO, Marc Ayers, told BioWorld.

    As yet, those kinds of treatments have been elusive. However, Initial results from Romark’s phase III study of NT-300 (nitazoxanide extended release) vs. placebo hit its primary endpoint in treating outpatients with mild or moderate COVID-19.

    The median time to sustained response, the primary endpoint, was about 13 days, similar to NT-300-treated subjects treated with placebo. A predefined subgroup of patients with mild disease demonstrated a median time to sustained response was reduced by 3.1 days with NT-300, a viral replication inhibitor, vs. placebo.

    In a secondary endpoint analysis, NT-300 was tabbed with an 85% reduction in progression to severe illness, which generally requires hospitalization, with only one subject moving on to severe COVID-19.

    In the predefined subgroup at high risk of severe illness according to CDC criteria, 5.6% of the placebo-treated subjects experienced severe illness compared to 0.9% of the NT-300-treated subjects.

    With those positive data in hand, Tampa, Fla.-based Romark said it plans to seek an emergency use authorization (EUA) from the FDA.

    Marc Ayers, CEO, Romark
    “The numbers are also very comparable to the numbers we’ve seen for monoclonal antibodies with an EUA,” Ayers said, adding that NT-300 has an advantage by virtue of its oral administration. Ayers also said the company is supplying the FDA with the information it needs but there is no specific timetable for further action that has been announced.

    The phase III study started in August and wrapped up in February. There were 1,092 participants in the randomized, parallel assignment, triple masked study. Male and female participants least 12 years of age had to show clinical signs and/or symptom that were consistent with worsening or stable mild or moderate COVID-19, including at least two respiratory symptom domains. They received two 300-mg nitazoxanide tablets or placebo twice a day for five days.

    In April 2020, Romark said it planned to start two trials for prevention of COVID-19 and other viral respiratory illnesses in high-risk populations, including elderly residents of long-term care facilities and health care workers. In both studies, participants were to receive either NT-300 or placebo for six weeks, with the primary endpoint being the rate of COVID-19 illness for NT-300 vs. placebo.

    Nitazoxanide was initially being developed by Romark to treat intestinal protozoan infections caused by Cryptosporidium parvum and Giardia lamblia but was found in preclinical studies to inhibit maturation of the SARS-CoV-2 spike protein.

    “When COVID-19 came, it was then obvious and we saw an opportunity,” Ayers said. “We found in the lab that the product was effective very quickly and saw opportunity to do the development.” Romark then went directly into its phase III study.

    Others are developing outpatient COVID-19 therapies. In July, AI Therapeutics Inc., of Guilford, Conn., began a randomized, double-blind, placebo-controlled study of up to 142 outpatients treated with LAM-002A to reduce viral load. LAM-002A is a PIKfyve kinase inhibitor that has demonstrated potent in vitro antiviral activity against several isolates of SARS-CoV-2, the virus responsible for COVID-193,4. Indeed, several studies now have shown that LAM-002A interferes with the entry and trafficking of the SARS-CoV-2 virus in cells. In July, AI Therapeutics, Yale University and the Quantitative Biosciences Institute at the University of California, San Francisco, began a phase II study of LAM-002A, with a primary efficacy endpoint being reduction of viral load in those with confirmed infection. Additional efficacy measures include death, hospitalization and oxygen saturation.

    In October, a phase I collaboration of Niagen (nicotinamide riboside) by Chromadex Corp. and Scandibio Therapeutics AB showed a 29% reduction in recovery time in 100 outpatients who received standard of care and nutritional protocol that included the agent, reducing average recovery time to 6.6 days vs. 9.3 days for placebo.

    A study of Reeqonus (favipiravir; Avigan) for outpatients with mild to moderate COVID-19 continues in North America by Fujifilm Holdings Corp.
  • b
    bob
    I just read a medical article referencing a surprising but positive study with infrared light and dementia. Apparently the light stimulates production of ATP. Sound familiar?
  • M
    Marshmallow
    Okay, here's a fun poll.
    Which disease will NR be used to treat first?

    1) Peripheral artery disease - at NW University tested with a 6 minute walk - Phase 3 now
    2) Covid - treated with ScandiBio cocktail in Turkey - Phase 3 completed and now in peer review
    3) Milk volume for moms with premies - at UC Davis - Phase 2 and Phase 3 listed on ClinicalTrials
    4) Chemotherapy-induced peripheral neuropathy - by Brunie at Scripts and/or Donna Hammond at U of Iowa
    5) Liver disease - NAFLD or Alcoholic Liver Disease
    6) Some other disease - take your pick

    Phase 3 trials listed on ClinicalTrials site
    https://clinicaltrials.gov/ct2/results?cond=&term=nicotinamide+riboside&cntry=&state=&city=&dist=&Search=Search&phase=2
    Search of: nicotinamide riboside | Phase 3 - List Results - ClinicalTrials.gov
    clinicaltrials.gov
  • D
    Dennis
    Free falling...
  • M
    MICHAEL
    Nagel et al should be reiterating their Buy ratings.
  • E
    Ezra
    New incredible anecdote up at RaisingNAD. Thank you Kirk!
  • D
    Donn
    Need one of our whale friends to break us out of this descending wedge pattern. Looks like we're close.
  • C
    C
    https://apple.news/AuV55dm_SRlCmthNMd26lUA

    While everyone is focusing on vaccines many other countries continue to struggle. Now if we could find something easy like vitamins that could possibly help before people are in a dire situation...
    The WHO said the global infection rate was approaching the highest so far.
    The WHO said the global infection rate was approaching the highest so far.
    apple.news
    Bullish
  • 0
    007
    @Stefan_001, I saw below that your are tracking the ranking of the SKU for Niagen. Could you let me know how you find this ranking? I would like to track it myself. And do you see that the ranking of Niagen is increasing over time or not at all? Thanks!
  • J
    Jeff Manzanita
    There have been over 31,000,000 million people in the US who have had COVID. Beyond the possibility of variants being with us indefinitely, a large number are experiencing long hauler effects. The Harvard study being conducted by Dr. Tanzi's group will be extremely interesting. That could lead to a huge market for NR. It is interesting as well that Dr. Tanzi has stepped outside his greatest known area of expertise to initiate that research. If he didn't expect good results, I would think he wouldn't spend his time here. https://www.health.harvard.edu/blog/the-tragedy-of-the-post-covid-long-haulers-2020101521173
    Many thousands of people in the US have recovered from COVID-19 but continue to experience feelings of exhaustion, little energy, and mental fogginess that linger for months –– possible signs of long COVID, or PASC. These "long haulers" grapple with
    Many thousands of people in the US have recovered from COVID-19 but continue to experience feelings of exhaustion, little energy, and mental fogginess that linger for months –– possible signs of long COVID, or PASC. These "long haulers" grapple with
    www.health.harvard.edu
  • M
    Mike
    Germany and Uk are out of Tru Niagen again. Is Tru Niagen really in short supply now?